Modality
Nanobody
MOA
CGRPant
Target
CD47
Pathway
Apoptosis
FTDADHDProstate Ca
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
~Jun 2023
→ ~Sep 2024
Phase 2
Dec 2024
Phase 2Current
NCT06393201
975 pts·Prostate Ca
2024-12→TBD·Active
975 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-102mo agoFast Track· FTD
Trial Timeline
2025Q2Q3Q42026
P2
Active
Catalysts
Fast Track
2026-02-10 · 2mo ago
FTD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06393201 | Phase 2 | Prostate Ca | Active | 975 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |